---
title: "Tetrahydrocarbazole Antibiotic Potentiator Restores Multiple Drugs Against Resistant Klebsiella pn"
id: "biorxiv-6-discovery-of-a-multi-class-antibiotic-potentiator-against-resistant-klebsiella"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-6-discovery-of-a-multi-class-antibiotic-potentiator-against-resistant-klebsiella"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.08.02.742369v1?rss=1"
published_at: "2026-08-03T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Tetrahydrocarbazole Antibiotic Potentiator Restores Multiple Drugs Against Resistant Klebsiella pn
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-6-discovery-of-a-multi-class-antibiotic-potentiator-against-resistant-klebsiella
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.08.02.742369v1?rss=1)
- **Published At:** 2026-08-03T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The rise of multidrug-resistant Gram-negative bacteria, particularly **Klebsiella pneumoniae**, limits available treatment options for pneumonia, bloodstream, urinary tract, and surgical-site infections. - Resistance-mitigating agents (RMAs) are compounds that can re-sensitize bacteria to existing antibiotics without intrinsic antibacterial activity; they represent a strategy to restore antibiotic efficacy. - A high-throughput screen of a 3,200-compound fragment-based library was performed against an MDR K. pneumoniae isolate in the presence of subinhibitory **ciprofloxacin** to identify RMAs. - The screen identified a **tetrahydrocarbazole**-containing molecule (designated compound 1) as a ciprofloxacin potentiator. - Structure–activity relationship (SAR) studies produced a difluorinated analog, designated **compound 5**, with improved potentiation properties. - **Compound 5** potentiated multiple antibiotic classes in MDR K. pneumoniae, reducing minimum inhibitory concentrations (MICs) by as much as reported (source text indicates up to ?16-fold reduction). - Synergistic interactions were observed between **compound 5** and antibiotics including ciprofloxacin, ceftriaxone, cefoxitin, and tetracycline across four genetically diverse MDR K. pneumoniae strains. - The authors propose that tetrahydrocarbazole-containing compounds are a promising new class of RMAs for further development against MDR K. pneumoniae. - This work is a preprint and has not been peer-reviewed; additional details such as toxicity, in vivo efficacy, and full MIC datasets were not reported in the abstract.
## Clinical Analysis & Structured Key Points
[](https://www.biorxiv.org/cdn-cgi/content?id=Kg1HLyZskRd1E_xkqELIfs70Dp9NIzGxZAcR2uYIb80-1785833445.368058-1.2.1.1-zwvs2qdiz_7iPqx2avtANkejPP4tU8a4u0W2nQ78C80) [Skip to main content](https://www.biorxiv.org/content/10.64898/2026.08.02.742369v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.08.02.742369v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # Discovery of A Multi-Class Antibiotic Potentiator Against Resistant Klebsiella pneumoniae [ View ORCID Profile](http://orcid.org/0009-0004-3675-8371)Susan Harris, [ View ORCID Profile](http://orcid.org/0000-0003-1920-118X)Somnath Dutta, Whitney Thong, [ View ORCID Profile](http://orcid.org/0009-0008-7878-9458)Megan Morris, Zoe Wang, XIANG WANG doi: https://doi.org/10.64898/2026.08.02.742369 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Susan Harris University of Colorado Boulder * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Susan%2BHarris%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Harris%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ASusan%2BHarris%2B) * [ORCID record for Susan Harris](http://orcid.org/0009-0004-3675-8371 "Open in new tab") Somnath Dutta University of Colorado Boulder * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Somnath%2BDutta%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Dutta%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ASomnath%2BDutta%2B) * [ORCID record for Somnath Dutta](http://orcid.org/0000-0003-1920-118X "Open in new tab") Whitney Thong University of Colorado Boulder * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Whitney%2BThong%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Thong%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AWhitney%2BThong%2B) Megan Morris University of Colorado Boulder * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Megan%2BMorris%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Morris%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AMegan%2BMorris%2B) * [ORCID record for Megan Morris](http://orcid.org/0009-0008-7878-9458 "Open in new tab") Zoe Wang University of Colorado Boulder * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Zoe%2BWang%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Wang%20Z&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AZoe%2BWang%2B) XIANG WANG University of Colorado Boulder * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=XIANG%2BWANG%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=WANG%20X&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AXIANG%2BWANG%2B) * For correspondence: xiang.wang@colorado.edu * [Abstract](https://www.biorxiv.org/content/10.64898/2026.08.02.742369v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5676943/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.08.02.742369v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5676943/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.08.02.742369v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5676943/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.08.02.742369v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5676943/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract The rapid rise of multidrug-resistant (MDR) bacterial infections has severely limited treatment options, particularly for Gram-negative pathogens such as Klebsiella pneumoniae, a leading contributor to pneumonia, bloodstream, urinary tract, and surgical-site infections. One strategy to restore antibiotic efficacy is the use of resistance-mitigating agents (RMAs), compounds that re-sensitize bacteria to existing antibiotics without displaying independent antibacterial activity. Herein, we report the results of a high-throughput screen of a 3,200-compound fragment-based library against an MDR K. pneumoniae isolate in the presence of subinhibitory ciprofloxacin. This screen identified a tetrahydrocarbazole-containing compound, 1, as a ciprofloxacin potentiator. Subsequent structure-activity relationship studies yielded a difluorinated analog, compound 5, which potentiated multiple antibiotic classes in MDR K. pneumoniae, reducing MICs up to ?16 fold. Further testing demonstrated synergistic interactions between compound 5 and ciprofloxacin, ceftriaxone, cefoxitin, and tetracycline across four genetically diverse MDR K. pneumoniae strains. These findings suggest that tetrahydrocarbazole-containing compounds constitute a promising new class of RMAs with potential for future development as therapies against MDR K. pneumoniae infections. Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.08.02.742369v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.64898/2026.08.03.742480v1 "Overcoming the accuracy-generalization tradeoff in docking and scoring for prospective virtual screening")[Next ](https://www.biorxiv.org/content/10.64898/2026.07.29.741451v1 "Transcranial Magnetic Stimulation Differentiates Egocentric vs. Allocentric Network Hubs for Memory-Guided Reach") Posted August 03, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.08.02.742369v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/08/03/2026.08.02.742369.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.biorxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Email](https://www.biorxiv.org/ "Email this Article") [ Share](https://www.biorxiv.org/) Discovery of A Multi-Class Antibiotic Potentiator Against Resistant Klebsiella pneumoniae Susan Harris, Somnath Dutta, Whitney Thong, Megan Morris, Zoe Wang, XIANG WANG bioRxiv 2026.08.02.742369; doi: https://doi.org/10.64898/2026.08.02.742369 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Share This Article: Copy [![Twitter logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.biorxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.08.02.742369v1%26text%3DDiscovery%2520of%2520A%2520Multi-Class%2520Antibiotic%2520Potentiator%2520Against%2520Resistant%2520Klebsiella%2520pneumoniae "Share this on Twitter") [![Facebook logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.biorxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.08.02.742369v1%26t%3DDiscovery%2520of%2520A%2520Multi-Class%2520Antibiotic%2520Potentiator%2520Against%2520Resistant%2520Klebsiella%2520pneumoniae "Share on Facebook") [![LinkedIn logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.biorxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.08.02.742369v1%26title%3DDiscovery%2520of%2520A%2520Multi-Class%2520Antibiotic%2520Potentiator%2520Against%2520Resistant%2520Klebsiella%2520pneumoniae%26summary%3D%26source%3DbioRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.biorxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.08.02.742369v1%26title%3DDiscovery%2520of%2520A%2520Multi-Class%2520Antibiotic%2520Potentiator%2520Against%2520Resistant%2520Klebsiella%2520pneumoniae "Share on Mendeley") [ Citation Tools](https://www.biorxiv.org/ "Citation Tools") [ Get QR code](https://connect.biorxiv.org/qr/2026.08.02.742369) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.biorxiv.org/content/10.64898/2026.08.02.742369v1&count=horizontal&via=&text=Discovery%20of%20A%20Multi-Class%20Antibiotic%20Potentiator%20Against%20Resistant%20Klebsiella%20pneumoniae&counturl=www.biorxiv.org/content/10.64898/2026.08.02.742369v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.biorxiv.org/content/early/recent) * [Animal Behavior and Cognition](https://www.biorxiv.org/collection/animal-behavior-and-cognition) (7845) * [Biochemistry](https://www.biorxiv.org/collection/biochemistry) (18361) * [Bioengineering](https://www.biorxiv.org/collection/bioengineering) (14525) * [Bioinformatics](https://www.biorxiv.org/collection/bioinformatics) (43409) * [Biophysics](https://www.biorxiv.org/collection/biophysics) (22123) * [Cancer Biology](https://www.biorxiv.org/collection/cancer-biology) (19239) * [Cell Biology](https://www.biorxiv.org/collection/cell-biology) (26354) * [Clinical Trials](https://www.biorxiv.org/collection/clinical-trials) (138) * [Developmental Biology](https://www.biorxiv.org/collection/developmental-biology) (13736) * [Ecology](https://www.biorxiv.org/collection/ecology) (20549) * [Epidemiology](https://www.biorxiv.org/collection/epidemiology) (2067) * [Evolutionary Biology](https://www.biorxiv.org/collection/evolutionary-biology) (25017) * [Genetics](https://www.biorxiv.org/collection/genetics) (15934) *
## Related Clinical Research

- [High prevalence of plasmid-borne ESBL and quinolone resistance in multidrug-resistant Escherichia](https://medichelpline.com/clinical-feed/biorxiv-3-high-occurrence-of-plasmid-mediated-quinolone-and-esbl-resistance-genes-among.md)
- [Genomic and antibiogram characterization of Pasteurella multocida type A from layer chickens](https://medichelpline.com/clinical-feed/plos-one-21-isolation-antibiogram-and-whole-genome-sequence-analysis-of-pasteurella.md)
- [Sales of veterinary antimicrobials in Bangladesh, 2023: volumes, classes and routes](https://medichelpline.com/clinical-feed/pubmed-42676771.md) (DOI: 10.2471/BLT.25.294366)
- [Trends in bacteraemia incidence and antimicrobial resistance, Calgary 2006–2022: genomic and presc](https://medichelpline.com/clinical-feed/medrxiv-4-trends-in-incidence-and-antimicrobial-resistance-for-five-major-causes-of.md)
- [Complicated UTIs Managed in Hospital-at-Home: Clinical, Microbiological Profile and Outcomes](https://medichelpline.com/clinical-feed/pubmed-42663904.md) (DOI: 10.1007/s10096-026-05648-5)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.